Informed and supported by mechanistic and epidemiological studies in large but also in specific patient cohorts, therapeutic targeted IgE, with its long tissue residency, direct tumour cell killing, and ability to repolarise tumour-supportive M2-like macrophages, likely represent a promising new means of tackling cancer and may improve survival in cancers with poor outcomes. Here, IGHE is linked to neoplasm.